carcinoma in situ of urinary bladder (DBCOND0106378)

Identifiers

Synonyms

Carcinoma in Situ of Bladder / Bladder cancer in situ / Carcinoma in situ of the urinary bladder / In situ Bladder Cancer / Carcinoma in situ of the bladder / Carcinoma in situ of bladder NOS / Carcinoma in situ of urinary bladder (disorder) / Malignant neoplasm of bladder stage 0, with cancer in situ / Bladder cancer stage 0, with cancer in situ

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
BCG vaccine	A vaccine indicated in the prevention of tuberculosis and the treatment of non-invasive urothelial bladder cancer.	No drug targets
Bacillus calmette-guerin substrain connaught live antigen	Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1...	No drug targets
Bacillus calmette-guerin substrain russian BCG-I live antigen	An intravesically-administered live BCG vaccine used to treat papillary urothelial cell carcinoma of the bladder.	No drug targets
Bacillus calmette-guerin substrain tice live antigen	A live attenuated vaccine against Mycobacterium bovis.	No drug targets
Epirubicin	An anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer.	DNA topoisomerase 2-alphatarget DNAtarget Multidrug resistance-associated protein 1transporter UDP-glucuronosyltransferase 2B7enzyme Cytosolic phospholipase A2enzyme DNA topoisomerase 2-betatarget
Hexaminolevulinate	An optical imaging agent used to perform Blue Light Cystoscopy (BLC™) in order to detect carcinoma of the bladder.	No drug targets

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03335059	Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.	Mitomycin	treatment	3	terminated
NCT01304173	Retrospective Chart Review of Valstar	No drug interventions	Not Available	Not Available	completed
NCT05375903	A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	Gemcitabine Imiquimod Zalifrelimab	treatment	1	recruiting
NCT02901548	Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder	Durvalumab	treatment	2	terminated